Keiji Ishida

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Nozomu Tanaka, Kazuki Sakamoto, Hiroyuki Okabe et al. · Oncology Reports · 2014 · 140 citations · Full text

Antitumor Activity, Medicine, Tumor Growth +14

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

Hiroshi Tsukihara, Fumio Nakagawa, Kazuki Sakamoto et al. · Oncology Reports · 2015 · 109 citations · Full text

Combination Chemotherapy, Medicine, Pharmacology +12

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

Kazuki Sakamoto, Tatsushi Yokogawa, Hiroyuki Ueno et al. · International Journal of Oncology · 2015 · 57 citations · Full text

Prior Therapies, Molecular Biology, Crucial Roles +19

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

Hiroaki Ochiiwa, Guzhanuer Ailiken, Masataka Yokoyama et al. · Oncogene · 2021 · 30 citations · Full text

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki, Igor Odintsov, Keiji Ishida et al. · Nature Cancer · 2023 · 30 citations · Full text